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Abstract 
Drug-drug interactions form a significant risk group for adverse effects associ-
ated with pharmaceutical treatment. These interactions are often reported in the 
literature, however, they are sparsely represented in machine-readable re-
sources, such as online databases, thesauri or ontologies. These knowledge 
sources play a pivotal role in Natural Language Processing (NLP) systems since 
they provide a knowledge representation about the world or a particular do-
main. While ontologies for drugs and their effects have proliferated in recent 
years, there is no ontology capable of describing and categorizing drug-drug in-
teractions. Moreover, there is no artifact that represents all the possible mecha-
nisms that can lead to a DDI. To fill this gap we propose DINTO, an ontology 
for drug-drug interactions and their mechanisms. In this paper we describe the 
classes, relationships and overall structure of DINTO. The ontology is free for 
use and available at https://code.google.com/p/dinto/ 
Keywords: Ontology, Drug-drug interactions, Text mining, Semantics, Pharma-
cology 
1 Introduction 
In recent years, ontologies have become important tools to support researchers in their 
efforts to remain up to date with the flood of emerging information. The domain of 
pharmacology has not been a stranger to the proliferation of ontologies and 
knowledge bases. RxNorm facilitates information exchange about medication among 
clinical systems [1], standardizing names for clinical drugs and for dose forms. 
SNOMED CT is the most comprehensive ontology of clinical terms for supporting 
health information systems [2], including different classifications of drugs and drug-
related information. MeSH [3], a controlled vocabulary thesaurus for indexing Med-
Line articles, contains a large amount of pharmacological information, including 
pharmacological actions of drugs. 
Drug-drug interactions (DDIs) are common adverse drug reactions having an im-
portant impact on patient safety and healthcare costs. Although there is a large num-
ber of drug databases and semi-structured resources (such as DrugBank [4], Stockley 
[5] and Drug Interactions Facts [6]) with information about DDIs, these databases are 
incomplete and the consistency of their content is limited, so it is very difficult to 
assign a real clinical significance to each interaction. Ontologies allow the formal 
representation of the knowledge in a particular domain. However, although several 
ontologies exist for the pharmacology domain, none covers all classes related to drug-
drug interactions. In fact, to the best of our knowledge, there are only three ontologies 
focusing in the representation of DDI information.  The first one, DIO [7] (Drug In-
teraction Ontology), is a formal representation of drug pharmacological actions, de-
picted by drug-biomolecule interactions that are the underlying mechanism in some 
types of DDIs. The second one is the PK ontology [8] that was developed for the rep-
resentation of drug pharmacokinetic information, and has been used to annotate 
pharmacokinetics studies of DDIs. The third one is the OWL version of the Drug 
Interaction Knowledge Base (DIKB) [9], an evidence taxonomy that, when combined 
with a set of inclusion criteria, enables drug experts to specify their confidence in a 
type of drug mechanism assertion. However, neither of these represents all the differ-
ent DDI mechanisms, consequences and additional factors. 
In this paper, we propose the first Drug Interaction Ontology (DINTO) that sys-
tematically organizes all DDI related information. This ontology represents all the 
possible mechanisms that can produce a DDI, including both types, pharmacodynam-
ic and pharmacokinetic mechanisms. Our final purpose is that this ontology can be 
used as a basis for developing NLP applications in the pharmacovigilance domain. In 
this work we describe the classes, relations, structure and organization of this newly 
developed ontology. DINTO is available in OWL for download at 
https://code.google.com/p/dinto/. 
2 Methods 
To build DINTO we follow the methodology for ontology development 
METHONTOLOGY [10], further supplemented with specific tasks relating to em-
bedding this ontology within the context of existing efforts, particularly those of the 
OBO Foundry [11]. 
2.1 Specification 
We defined the ontological requirements for a comprehensive ontology that will rep-
resent all the information related to the domain of DDIs and that should be mapped to 
other ontologies. During this step we defined different competency questions (CQs) 
that will be used as a type of requirement specification and evaluation for the finished 
ontology. 
2.2 Knowledge Acquisition 
Prior to the present work, we created a manually annotated corpus, the DDI corpus 
[12]. This corpus was used in the initial stages of the ontology creation process, which 
led to the identification of basic concepts in the DDI domain and relations between 
them. 
Firstly, we used the UAM Corpus tool,1 a free environment for linguistic annota-
tion of text corpora. This tool enables the annotation of selected segments in the cor-
pus, with various features or labels. The study of the annotated segments was used for 
identification of linguistic patterns in these texts. For example, in the analysis of an-
notated segments in the corpus labelled “pharmacodynamic effects of a drug” we 
identified five main ways a clinical consequence of a DDI can be described:  
 The effect of a DDI is the effect of a drug: e.g. “increase the adrenergic effect of”, 
“reduced the action of”.  
 The effect of a DDI refers to a negative effect of a drug: e.g. “the adverse effect 
of”, “the ototoxic potential of”.  
 The effect of a DDI refers to the signs or symptoms, generally related to an adverse 
effect, without explicitly relating them with a drug: e.g. “serious reactions such as 
rigidity, myoclonus, or autonomic instability”.  
 The effect of the DDI provides information regarding some aspect of the DDI: e.g. 
“additive CNS depressant effect”, “observed an excessive reduction of blood pres-
sure”. 
 The effect is expressed through a modification in some analytical test result: e.g. 
“increase in prothrombin time”.  
Secondly, we conducted a keyword analysis with the freeware AntConC corpus anal-
ysis toolkit2 and computed a concordance analysis of relevant terms. The outcome of 
this activity is a list of relevant concepts and their relationships with other concepts. 
For example, through this analysis we identified those terms used to described a mod-
ification or alteration (increase, decrease, potentiation, etc.) and analysed the con-
cepts in the domain that are usually related with them. For example, the concept en-
hanc* can be used with terms classified as “pharmacokinetic parameter”, “pharmaco-
kinetic process”, “effect” or “toxicity”; however, the term elevat* is only used in our 
corpus with terms classified as “concentration” and “pharmacokinetic parameter”. 
Another important source of information is provided by other ontologies that can 
potentially be re-used and imported to our ontology. We reviewed different ontologies 
that were identified as related to some aspect of DDIs. A brief description of the most 
prominent ontologies in this domain is provided in section 3.3 Related Ontologies. 
2.3 Conceptualization 
In the conceptualization of DINTO, the most important and challenging aspect was 
the construction of the basic schema that relates the pharmacodynamics and pharma-
cokinetics aspects of an individual drug and the DDI aspects, since creating specific 
boundaries between these domains is not possible. A simplified schema is illustrated 
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in Figure 1, which shows the integration between the pharmacokinetics and pharma-
codynamics aspects of an individual drug and how they are related with a DDI.  
 
Fig. 1. Diagram for pharmacokinetic and pharmacodynamic aspects of a DDI. 
In the schema, the pharmacokinetic information is shown in section 1, which repre-
sents how a drug undergoes different pharmacokinetic processes in the body (absorp-
tion, distribution, metabolism and excretion). These processes determine the concen-
tration of the drug in the body (in the blood and in the different tissues). The concen-
tration of the drug determines its effect.  
The pharmacodynamic information is shown in section 2: a drug binds different pro-
teins in the body. The target is the one that regulates (facilitates or impairs) the activi-
ty of the drug and this activity regulates (facilitates or impairs) the effect of the drug 
in the body. As is shown in the figure, a drug can have different effects (therapeutic, 
adverse or toxic).  
Section 3 represents that a DDI is a process involving exactly two drugs, one of them 
is the Precipitant and the other one is the Object. A drug that is a precipitant has an 
is_precipitant_in relationship with a DDI; a drug that is an object has an is_object_in 
relationship with a DDI. The precipitant is the one that leads to the occurrence of the 
DDI, the one that triggers the mechanisms. Therefore, a drug is a precipitant, as well, 
if it has an is_agent_in relationship with a DDI Mechanism. On the other hand, the 
object is the victim in the interaction. Therefore, it will be a drug that has a relationhip 
undergoes, has_concentration or has_effect with an effect or concentration that is 
altered by a DDI Mechanism. There are two types of DDI mechanisms, pharmacoki-
netic mechanism and pharmacodynamic mechanism. The former one implies the al-
teration in a pharmacokinetic process of a drug, which, as is shown in the schema, 
will alter the concentration of the drug in the body and, consequently, its effects. The 
latter one affects to the target, leading to an alteration (an increase or a decrease) in 
the drug effect. There are different types of pharmacokinetic and pharmacodynamic 
mechanism. Some examples are described and represented in section 3.5 Use Cases.  
2.4 Implementation 
The implementation language is the Web Ontology Language 2 (OWL2) and we have 
used the Protégé ontology editing software3.  
2.5 Evaluation 
We plan to evaluate the ontology in use for two different applications: prediction of 
DDIs on the basis of their mechanism, and text mining the pharmacological literature. 
However, for the time being our evaluation has consisted of two approaches: 1) clas-
sification scenario testing and 2) supporting or answering of previously established 
CQs. Additionally, we have invited peer review of the ontology. 
The first one allows checking the consistency and expressivity of the ontology and 
the detection of errors through a manual iterative review of the inferred relationships 
and classifications. For this classification scenario testing, we have added individuals 
to the ontology with associated properties. Each one of these test sets represent a real 
DDI caused by a specific DDI mechanism. Through this method, we tested that per-
forming classification has resulted in the individuals being detected as members of the 
correct target classes (instance checking) and that the inferred relationships are those 
expected.  
With the second approach we check if the ontology satisfies the ontology require-
ments established in the specification step through the use of the created CQs. Table 1 
shows a sample of them and their corresponding axioms as an example of how the 
ontology corresponds to the requirements of the competency questions (the examples 
are related to the interaction between Cyclosporin and Rosuvastatin explained in sec-
tion 4.1 Use Case of a pharmacokinetic DDI). 
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Table 1. Competency Questions and corresponding axioms in the ontology that can be used to 
derive answers.  
Question Axiom Example 
Is there an interac-
tion between DrugA 
and DrugB? 
DDI has_participant 
Participant 
DDI has_precipitant 
Precipitant 
DDI has_object  
Object  
CyclosporinRosuvastatin  
is_a DDI 
CyclosporinRosuvastatin 
has_precipitant Cyclosporin 
CyclosporinRosuvastatin 
has_object Rosuvastatin 
Is the effect of Dru-
gA modified by 
DrugB? 
Precipitant alters  
Drug Effect 
Cyclosporin increases  Rhabdo-
myolisis 
Rhabdomyolisis  
is_effect_of 
Rosuvastatin 
What is the mecha-
nism of the interac-
tion between DrugA 
and DrugB? 
DDI is_preceded_by  
DDI Mechanism 
CyclosporinRosuvastatin 
is_preceded_by  
OATP1B1 Inhibition 
OATP1B1 Inhibition  
is_a  
Pharmacokinetic Mechanism 
Is there a PK inter-
action between  
DrugA and DrugB? 
Pharmacokinetic DDI 
is_preceded_by 
Pharmacokinetic Mecha-
nism 
CyclosporinRosuvastatin 
is_preceded_by  
OATP1B1 Inhibition 
OATP1B1 Inhibition is_a Phar-
macokinetic Mechanism 
3 Structure of DINTO 
The current version of the developed ontology DINTO is an OWL artifact containing 
396 classes, 67 object properties and 3,317 axioms, prior to the import of other ontol-
ogies. In this section we describe the main classes in DINTO. Thereafter, we define 
the object properties and show an example of the use of chained properties in the 
ontology. Finally, a description of the related and imported ontologies is also provid-
ed. 
3.1 Classes 
The different classes in the ontology represent all the DDI-related knowledge. The 
information regarding DDIs and represented in the ontology can be divided into three 
main groups: drug-related information, DDI-related information, and information 
relevant to the domain but not specifically related to drugs or DDIs. 
Drug related information refers to those classes that are not specific to DDIs and, 
therefore, are within the scope of other biomedical ontologies. These include: 
 The drugs themselves: for example, norfloxacin or duloxetine. These are imported 
from the ChEBI Ontology4 [13]. 
 The effects of the drugs: such as antihypertensive effect or nephrotoxic effect. The 
effect of a drug can be classified in DINTO in three main classes (see Figure 1):  
therapeutic effect (the intended use of the drug), adverse effect or toxic effect (un-
desirable effects of a drug). These will be taken from ChEBI and databases such as 
SIDER5.   
 The role or bioactivity of a drug: agonist, inhibitor, etc. These roles are specifically 
related with a protein included in the ontology. For example, the class “inhibitor” 
has as a child the class “CYP3A4 inhibitor”. 
 The pharmacokinetic processes that drugs undergo in the body: absorption, distri-
bution, metabolism or excretion.  
 The pharmacokinetic parameters describing these processes and the concentrations 
of drugs in the body: area under the curve or Cmax, for example.  
 The drug related procedures intended to avoid or reduce the effects of the DDI: 
reduction in drug dose, separation of the administration of the drugs by a minimal 
interval of time, etc. 
 The drug factors that can affect the effect and severity of a DDI: such as dosage or 
pharmaceutical form. 
DDI related information refers to those classes specifically related to DDIs. They are 
shown within a yellow box in Figure 1: 
 The DDIs themselves: the interaction between two drugs. Every DDI between two 
specific drugs is a class, such as Cyclosporin-Rosuvastatin DDI, that refers to the 
specific process in which cyclosporin interacts with rosuvastatin through a specific 
mechanism. For the time being, only the class DDI and the subclasses pharmacoki-
netic DDI (PkDDI) and pharmacodynamic DDI (PdDDI) have been created. In fu-
ture work, specific DDIs will be created for each interacting pair. 
 The mechanism of a DDI: such as the inhibition of the metabolic enzyme of one 
drug by another drug. Every DDI mechanism is a class that is defined on the basis 
of other entities and object properties. For example, the inhibition of the membrane 
transporter OATP1B1 is a class named “hepatocyte basolateral OATP1B1 inhibi-
tion”. It is defined as a DDI mechanism that has_agent a precipitant that inhibits 
the transporter OATP1B1. 
 The effect of a DDI: the consequence in the patient as a result of the interaction 
between two drugs.  
The remaining classes are important in the DDI domain, but are not specifically relat-
ed to drugs or DDIs.  
 The sources of information that can describe a DDI: a controlled study, a case re-
port.  
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 The target to which a drug binds: calcium channel, beta-adrenergic recptor, etc.  
 Metabolic enzymes: such as CYP1A2 or UDP-glucuronosyltransferase.  
 Transporters and drug efflux pumps: albumin, P-glycoprotein.  
 Patient factors that can affect the effect and severity of a DDI: age, diseases or 
genetic factors.   
All these classes are defined in natural language following Aristotelian principles, and 
OWL definitional axioms are captured where appropriate and possible. For example, 
the class precipitant is a subclass of the class drug and is defined as: “A precipitant is 
a participant that alters the disposition and/or effects of another drug by triggering a 
DDI mechanism.” The OWL definitional axiom for precipitant is:  
(„is agent in‟ some „DDI mechanism‟) or  
(drug and  
(alters some „pharmacokinetic process‟) 
In combination with the object properties, these OWL definitions are responsible for 
the inference capabilities of DINTO.  
3.2 Relationships 
We follow the OBO community effort to standardize the relationships used in bio-
medical ontologies [14]. 
The current version of DINTO contains 67 object properties. These object proper-
ties are important for inferences, enabled by the explicit specification of domains and 
ranges for some of these object properties and from the creation of property chains 
between them. Through the use of chained properties we can represent ordered phar-
macological events. 
During the analysis of the DDI corpus, we identified multiple ways in which an in-
teraction between two drugs can be expressed. Therefore, the relationship inter-
acts_with in the ontology is one of the most complex. Moreover, it has multiple prop-
erty chains. An example is shown in Figure 2. 
 
  Fig. 2. Description of the relationship interacts_with 
The object property interacts_with is a symmetric relationship that has domain and 
range “drug”. It is a subproperty of the property chain:  
decreases o is_effect_of → interacts_with 
The relationship is_effect_of is defined as “A relationship between an effect and the 
chemical that produces it”. It has “drug effect” as domain and “drug” as range. 
The relationship decreases is a subproperty of the relationship alters and sibling to the 
relationship increases. Decreases is defined in DINTO as “A relationship between an 
entity x (process or continuant) and an entity y, which bears a quality that is de-
creased by x, leading to a change that is decreased compare to normal or previous 
value”. Therefore, it can have as domain or range any entity (continuant or process). 
In the same way as interacts_with, decreases is a subproperty of different chained 
properties. For example:  
blocks o facilitates → decreases 
The relationship blocks is defined as “A relationship between a drug x and a recep-
tor or ion channel (y), where (x) ‘binds to but does not activate (y) thereby blocking 
the actions of endogenous or exogenous (y)-agonists.‟”. It has domain “drug” and 
range “protein”.  
The relationship facilitates is a subproperty of the relationship regulates and sib-
ling to the relationship impaires. The definition of facilitates is “A relationship be-
tween an entity x (continuant or process) and a process y, which occurrence depends 
directly or is heavily dependent on x”. It has as domain any entity and as range the 
union of the classes “physiological effect” and “pharmacokinetic process”. 
3.3 Related Ontologies 
An analysis of related ontologies was performed. The following ontologies were iden-
tified as useful knowledge sources, and subsets from them were integrated into 
DINTO.  
 Basic Formal Ontology6: We follow BFO‟s definitions for upper level classes such 
as Process and Disposition in our work.  
 OBO Ontology Metadata7: The OBO ontology metadata project standardises anno-
tation properties for common annotation types such as definition, synonym and so 
on. We import the ontology-metadata.owl (a subset of the IAO8). 
 Relation Ontology [14]: RO is a collection of relations intended primarily for 
standardization across ontologies in the OBO Foundry and wider OBO library. We 
map our relations to RO where appropriate.   
 Semanticscience Integrated Ontology9: We map our relations to SIO where no 
appropriate RO mapping is available.  
 Chemical Entities of Biological Interest [13]: ChEBI includes many drugs and their 
biological roles, and we use it as a source for terminology and role relationships.   
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 Functional Therapeutic Classification System10: FTC sorts over a thousand ap-
proved drugs based on their mode of action. The FTC features over 20'000 catego-
ries defining the pharmacology of therapeutic agents.  
 PK Ontology [8]: This ontology is used as a source for terminology, definitions 
and units in this area.  
 Drug Interaction Ontology [7]: We use DIO as a model for relating DDI mecha-
nisms to their locations.  
 DIKB [9]: We map our has_object and has_precipitant relationships with their 
equivalents in DIKB.  
4 Use Cases 
In this section we explain two use cases for the ontology, representing the two main 
types of mechanism. 
DINTO has been designed to represent all possible mechanisms that can lead to a 
DDI. The ontology provides the general pharmacological principles of the domain. 
Based on this general knowledge it is possible to establish specific DDIs between 
specific pairs of drugs. Every DDI mechanism is manually conceptualized and incor-
porated into the basic schema (Figure 1). To check the consistency of this general 
conceptualization, a specific real example in the DDI domain is selected for every 
DDI mechanism. A test set of individuals is created in the ontology and the minimal 
number of relationships between them is explicitly established. Through the use of a 
reasoner (such as Fact++), we check the consistency and review that the classification 
of entities as well as the inferred object properties are the expected ones and con-
sistent with the literature. 
In this paper we described two of these examples, one for a pharmacokinetic DDI and 
one for a pharmacodynamic DDI. 
4.1 Use case of a pharmacokinetic DDI 
Different membrane transporters are important in the pharmacokinetics of drugs, 
since they can affect the drug disposition, its therapeutic efficacy and its adverse drug 
reactions. They are very important, as well, as a mechanism for pharmacokinetic 
DDIs. For example, the drug rosuvastatin is transported into the hepatocyte, where it 
is metabolized and inactivated, through the transporter OATP1B1. Several drugs in-
hibit the activity of this protein, which may result in lower hepatic intracellular and 
higher blood concentrations of OATP1B1 substrates. For instance, an increase in the 
area under the curve (AUC) of rosuvastatin has been described when co-administered 
with the OATP1B1 inhibitor cyclosporine [15]. 
The first example is represented in Figure 3. The drug “Cyclosporine” inhibits the 
activity of the protein “OAT1B1”. This protein is related, as we said, with the phar-
macokinetics of the drug “Rosuvastatin” in the way that is shown in the figure. There-
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fore, “Cyclosporine” is classified as a “Precipitant” (the one that triggers the DDI) 
and “Cyclosporine” is classified as “Object” (the one that is victim in the DDI). 
Moreover, the ontology classifies the pharmacokinetic process “Rosuvastatin Metabo-
lism” as “Decreased Metabolism”, whereas the concentration and effects of rosuvas-
tatin are classified as “Increased Concentration” and “Increased Effect”. It is inferred 
in this example that “Cyclosporine” decreases the metabolism of “Rosuvastatin” and 
that “Cyclosporine” increases its concentration and its effect. Moreover, the symmet-
ric interaction interacts_with between both drugs is inferred as well. 
 
Fig. 3. DDI between Cyclosporin and Rosuvastatin. Black arrows are the established relation-
ships; red arrows are the inferred relationships and grey boxes are the inferred classifications 
for the individuals. 
Figure 4 shows how the same relationships are inferred when we use a different test 
set and preliminary relationships to represent the same example. In this case, we cre-
ate an individual representing the DDI, “Cyclosporine-Rosuvastatin DDI”, as well as 
the mechanism, “OATP1B1 inhibition”. As it is shown in the figure, the DDI is clas-
sified as a pharmacokinetic DDI just in basis of the mechanism by which is preceded. 
 Fig. 4. DDI between Cyclosporin and Rosuvastatin. Black arrows are the established relation-
ships; red arrows are the inferred relationships and grey boxes are the inferred classifications 
for the individuals. 
4.2 Use case of a pharmacodynamic DDI 
 
Drugs binding the same target but presenting different activities can be involved in a 
DDI by an antagonistic mechanism. This is the case of the opioid receptor antagonist 
naloxone, which binds to the receptor without triggering a response, and different 
opioid agonists, such as propoxyphene, in which their activity is determined by these 
receptors. In cases of overdosage of propoxyphene, an increase in the undesirable 
effects such as central nervous system depression can be observed. Naloxone is used 
as an antidote in these cases, since the interaction between these two drugs will lead 
to a decrease in the effects of the agonist [15]. 
In Figure 4 we show the test set created for this example. Since “Propoxyphene” acti-
vates the “Opioid Receptor” and this facilitates the effects of this drug, the introduc-
tion of another drug, “Naloxone”, which blocks the activity of the receptor will lead to 
a decrease in the effects of the former one. As is shown in the figure, the ontology 
infers these decreases relationships as well as the interacts_with relationship. 
 
Fig. 5. DDI between Naloxone and Propoxyphene. Black arrows are the established relation-
ships; red arrows are the inferred relationships and grey boxes are the inferred classifications 
for the individuals. 
5 Conclusion 
In this paper we have described a comprehensive ontology that represents all the in-
formation related to the domain of DDIs and their mechanisms. A DDI is a process 
involving two drugs, which occurs as the consequence of another process (called the 
mechanism), which is triggered by one of the drugs. As a result, the concentrations or 
effects of the second drug are altered. The consequence for a specific patient will 
depend on different factors. These include patient related factors, such as the age, 
diseases, or genetic factors, and drug related factors, for example, mode of action, 
toxicity, dosage or administration mechanism route. The clinical relevance or signifi-
cance of a DDI is related to the type and magnitude of the effect, and is defined by 
several different factors [6]. These include the documentation about the DDI, includ-
ing the types of studies, the subjects where it has been observed, the onset of appari-
tion of the effects and its severity.  
Depending on all these aspects, different procedures allow to prevent or reduce the 
undesirable effect of a DDI, such as avoiding the co-administration of both drugs, 
monitoring the patient for the early detection of an effect due to the DDI, or the ad-
justment of the dosage of one or both interacting drugs.  
An important aspect in DINTO is the classification of drugs into different groups. 
Authors describing DDIs usually refer to a DDI as an interaction between an individ-
ual drug and a group of drugs or between two groups of drugs [16], [17]. During the 
analysis of the DDI Corpus it was observed that, usually, the selected characteristic 
for the group of drugs described suggests relevant information about some aspect of 
the DDI, such as its effect. Therefore, the inclusion of different classifications of 
drugs will be fundamental to the improvement of DINTO. Some interesting classifica-
tions for this purpose are the previously mentioned FTC or the ongoing project 
ADRM [18], which will allow the classification of drugs according to their adverse 
effects. 
We are working to follow the OBO Foundry principles. All the entities in the on-
tology have numerical identifiers. In future work we plan to map to BFO as our upper 
ontology. The relevant information found in the related ontologies and included in our 
conceptual models will be imported. Finally, we will evaluate the ontology for predic-
tion of DDIs on the basis of their mechanisms and for the application of text mining 
from pharmacological texts, although we anticipate that it may find additional use 
amongst domain experts once it is further developed. 
The ontology described in this work is available at 
https://code.google.com/p/dinto/.  
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